Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Income from Continuing Operations (2023 - 2025)

Immunocore Holdings' Income from Continuing Operations history spans 3 years, with the latest figure at 30027000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 26.55% year-over-year to 30027000.0; the TTM value through Dec 2025 reached 35514000.0, up 30.48%, while the annual FY2025 figure was 35514000.0, 30.48% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 30027000.0 at Immunocore Holdings, down from 177000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 8693000.0 in Q3 2024 and bottomed at 30027000.0 in Q4 2025.
  • The 3-year median for Income from Continuing Operations is 14311500.0 (2023), against an average of 11824000.0.
  • The largest annual shift saw Income from Continuing Operations soared 858.43% in 2024 before it crashed 102.04% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 19731000.0 in 2023, then fell by 20.26% to 23728000.0 in 2024, then decreased by 26.55% to 30027000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Income from Continuing Operations are 30027000.0 (Q4 2025), 177000.0 (Q3 2025), and 10333000.0 (Q2 2025).